As filed with the Securities and Exchange Commission on June 16, 2026

Registration No. 333-272355

Registration No. 333-237599

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Post-Effective Amendment No. 1 to Form S-4 Registration Statement No. 333-272355

Post-Effective Amendment No. 1 to Form S-4 Registration Statement No. 333-237599

 

FORM S-4

REGISTRATION STATEMENT
UNDER

THE SECURITIES ACT OF 1933

 

 

ASSERTIO HOLDINGS, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

 

Delaware		85-0598378
(State or Other Jurisdiction of Incorporation or Organization)		(IRS Employer Identification No.)

 

100 South Saunders Road, Suite 300
Lake Forest, Illinois 60045

(Address of Principal Executive Offices, including Zip Code)

 

Crystal Fisher

Zydus Pharmaceuticals (USA) Inc., 73 Route 31 N., Pennington, New Jersey 08534
Tel. (609) 730-1900

(Name, Address and Telephone Number, including Area Code, of Agent for Service)

 

Copies to:

 

Ryan A. Murr

Branden C. Berns

Evan D’Amico

Gibson, Dunn & Crutcher LLP

One Embarcadero Center, Suite 2600

San Francisco, California 94111-3715

(415) 393-8373

 

Krishna Veeraraghavan

Chelsea Darnell

Paul, Weiss, Rifkind, Wharton & Garrison LLP

1285 Avenue of the Americas

New York, New York 10019

(212) 373-3000

 

Approximate date of commencement of proposed sale to the public: Not applicable.

 

If the securities being registered on this Form are being offered in connection with the formation of a holding company and there is compliance with General Instruction G, check the following box. ¨

 

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨

 

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer		¨		Accelerated filer		x
Non-accelerated filer		¨		Smaller reporting company		x
Emerging growth company		¨

 

 

DEREGISTRATION OF SECURITIES

 

These Post-Effective Amendments (these “Post-Effective Amendments”) relate to the following Registration Statements on Form S-4 (each, a “Registration Statement”, and collectively, the “Registration Statements”) of Assertio Holdings, Inc., a Delaware corporation (the “Registrant”), filed with the U.S. Securities and Exchange Commission (the “SEC”): (i) Registration Statement on Form S-4 (No. 333-272355), filed with the SEC on June 2, 2023, as amended, and declared effective on June 15, 2023, pertaining to the registration of up to 45,449,280 shares of the Registrant’s common stock issuable to stockholders of Spectrum Pharmaceuticals, Inc. in connection with the merger contemplated thereby; and (ii) Registration Statement on Form S-4 (No. 333-237599), filed with the SEC on April 8, 2020, as amended, and declared effective on April 20, 2020, pertaining to the registration of up to 43,860,220 shares of the Registrant’s common stock issuable in connection with the merger transactions involving Assertio Therapeutics, Inc. and Zyla Life Sciences.

 

On May 13, 2026, the Registrant entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Zydus Worldwide DMCC, a limited liability company incorporated under the laws of the United Arab Emirates (“Parent”), Zara Merger Sub Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (“Purchaser”), and, solely for purposes of Section 9.20 thereof, Zydus Pharmaceuticals (USA) Inc., a New Jersey corporation. Pursuant to the Merger Agreement, on May 18, 2026, Purchaser commenced a tender offer (the “Offer”) to purchase all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Registrant (the “Shares”) at a price of $23.50 per Share, payable in cash, without interest and subject to any applicable withholding of taxes. The Offer expired one minute after 11:59 p.m., Eastern Time, on June 15, 2026, and on June 16, 2026, Purchaser irrevocably accepted for payment all Shares validly tendered and not validly withdrawn pursuant to the Offer. On June 16, 2026, pursuant to the Merger Agreement and in accordance with Section 251(h) of the General Corporation Law of the State of Delaware, Purchaser merged with and into the Registrant (the “Merger”), with the Registrant continuing as the surviving corporation and a wholly-owned subsidiary of Parent.

 

The foregoing description of the Offer, the Merger, the Merger Agreement and the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety by, the Merger Agreement, which is attached as Exhibit 2.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on May 13, 2026.

 

As a result of the Merger, the Registrant has terminated any and all offerings and sales of its securities pursuant to the Registration Statements. In accordance with an undertaking made by the Registrant in each of the Registration Statements to remove from registration, by means of a post-effective amendment, any of the securities registered under the Registration Statements that remain unsold at the termination of the offerings, the Registrant hereby terminates the effectiveness of each Registration Statement and removes from registration all of the securities that remain unsold under the Registration Statements as of the date hereof, if any.

 

The Registrant is filing these Post-Effective Amendments to withdraw and remove from registration all securities registered pursuant to the Registration Statements that remain unsold as of the date hereof. Each Registration Statement is hereby amended, as appropriate, to reflect the deregistration of such securities.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act, the registrant has duly caused these Post-Effective Amendments to the registration statements to be signed on its behalf by the undersigned, thereunto duly authorized, in Pennington, New Jersey, on June 16, 2026.

 

	ASSERTIO HOLDINGS, INC.
	By: /s/ Ravi Yadavar
	Name: Ravi Yadavar
	Title: Treasurer

 

No other person is required to sign these Post-Effective Amendments in reliance upon Rule 478 under the Securities Act of 1933, as amended.

 

 

SEC Filings